Strattera Patent: Lilly Wins Infringement, But Inequitable Conduct Claims Continue
Executive Summary
Lilly won a court ruling that seven generic manufacturers are infringing its Strattera (atomoxetine) patent. But the court declined to throw out claims by the generic firms that Lilly engaged in inequitable conduct in prosecuting the patent before the Patent and Trademark Office
You may also be interested in...
Lilly Prepares for Sales Pressures in 2011 to 2014
Facing a patent cliff, the Indianapolis company affirms faith in its pipeline, emerging markets strategy, and bolt-on deals.
Inequitable Conduct: Drug Industry Implores Federal Circuit To Revise Standard For Finding Deception In Patent Prosecution
The pharmaceutical industry has jumped at the opportunity to weigh in on a case that could change how courts determine whether patent owners deceived the U.S. Patent and Trademark Office in obtaining their patents
Inequitable Conduct: Drug Industry Implores Federal Circuit To Revise Standard For Finding Deception In Patent Prosecution
The pharmaceutical industry has jumped at the opportunity to weigh in on a case that could change how courts determine whether patent owners deceived the U.S. Patent and Trademark Office in obtaining their patents